Sugi Predict

Sugi Predict / Compounds / SCHEMBL7581332

SCHEMBL7581332

SCHEMBL7581332

Cc1ncc(C(N)=O)nc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT6 Q8N6T7 2/20 0.46
▸ DGAT1 O75907 2/20 0.43
▸ SOAT1 P35610 1/20 0.43
▸ ADORA3 P0DMS8 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MC4R P32245 1/20 0.42
▸ ADRA1A P35348 1/20 0.42
▸ MC3R P41968 1/20 0.42
▸ LMNA P02545 1/20 0.39
▸ TGFBR1 P36897 2/20 0.38
▸ KMT2A Q03164 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ LCK P06239 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NNMT P40261 3/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ DPP4 P27487 1/20 0.35
▸ DPP8 Q6V1X1 1/20 0.35
▸ SIRT3 Q9NTG7 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30441778 1.00 SIRT6 (0.46) SIRT6DGAT1SOAT1ADORA3TSHR
SCHEMBL15542179 0.82 SIRT6 (0.42) SIRT6DGAT1SOAT1ADORA3TSHR
SCHEMBL12606645 0.80 SMN1; SMN2 (0.41) KMT2AKDM4ESMN1; SMN2
SCHEMBL30112000 0.80 ALOX15 (0.48) TSHRLMNAKMT2AKDM4ETDP1
SCHEMBL702638 0.80 ALOX15 (0.48) TSHRLMNAKMT2AKDM4ETDP1
SCHEMBL31046828 0.80 DGAT1 (0.49) SIRT6DGAT1SOAT1
SCHEMBL2221067 0.79 NNMT (0.40) SIRT6DGAT1SOAT1ADORA3TSHR
SCHEMBL31696048 0.79 SIRT6 (0.40) SIRT6DGAT1SOAT1ADORA3TSHR
SCHEMBL30301164 0.79 DGAT1 (0.40) SIRT6DGAT1SOAT1ADORA3TSHR
SCHEMBL31156762 0.79 SIRT6 (0.40) SIRT6DGAT1SOAT1ADORA3TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117653636-B Anticancer medicine containing condensed bicyclo compound and pharmaceutical use of the compound 上海瑛派药业有限公司 2024-04-26 — — CN claimed
CN-117653636-A Anticancer medicine containing condensed bicyclo compound and pharmaceutical use of the compound 上海瑛派药业有限公司 2024-03-08 — — CN claimed
EP-4326713-A1 SUBSTITUTED FUSED BICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF Impact Therapeutics (Shanghai), Inc. (CN) 2024-02-28 — — EP claimed
CN-116783181-A Substituted fused bicyclic compounds as PARP inhibitors and use thereof 上海瑛派药业有限公司 2023-09-19 — — CN claimed
CN-1308536-A Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists BRISTOL MYERS SQUIBB CO (US) 2001-08-15 — — CN claimed
US-20250312335-A1 FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR BIOMEA FUSION, INC. 2025-10-09 — — US disclosed
US-20250136558-A1 PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 BIOMEA FUSION, INC. 2025-05-01 — — US disclosed
US-20240262795-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 BIOMEA FUSION, INC. 2024-08-08 — — US disclosed
CN-117653636-B Anticancer medicine containing condensed bicyclo compound and pharmaceutical use of the compound 上海瑛派药业有限公司 2024-04-26 — — CN disclosed
CN-113453764-B 7H-pyrrolo [2,3-d ] pyrimidin-4-amine derivatives 大鹏药品工业株式会社 2024-04-16 — — CN disclosed
US-11945785-B2 Pyrazine compounds as inhibitors of FLT3 BIOMEA FUSION, INC. (US) 2024-04-02 — — US disclosed
CN-117653636-A Anticancer medicine containing condensed bicyclo compound and pharmaceutical use of the compound 上海瑛派药业有限公司 2024-03-08 — — CN disclosed
CN-111108092-A Arylamide Kv2.1 inhibitor and preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2020-05-05 — — CN disclosed
CN-105566324-B Hydroxyl purine compound and application thereof 广东众生睿创生物科技有限公司 2020-04-03 — — CN disclosed
CN-106458932-A Phosphatidylinositol 3-kinase inhibitors 吉利德科学公司 2017-02-22 — — CN disclosed
EP-0680955-B1 PROCESS FOR PRODUCING N-tert-BUTYL-2-PYRAZINECARBOXAMIDE AND N-tert-BUTYL-2-PIPERAZINECARBOXAMIDE KOEI CHEMICAL CO (JP) 2002-09-18 — — EP disclosed
US-5922873-A Process for preparing N-tert-butyl-2-pyrazinecarboxamide and N-tert-butyl-2-piperazinecarboxamide KOEI CHEMICAL CO., LTD. (JP) 1999-07-13 — — US disclosed
US-5734055-A Process for preparing N-tert-butyl-2-pyrazinecarboxamide and N-tert-butyl-2-piperazinecarboxamide KOEI CHEMICAL CO. LTD. (JP) 1998-03-31 — — US disclosed
EP-0680955-A1 PROCESS FOR PRODUCING N-tert-BUTYL-2-PYRAZINECARBOXAMIDE AND N-tert-BUTYL-2-PIPERAZINECARBOXAMIDE KOEI CHEMICAL CO., LTD. (JP) 1995-11-08 — — EP disclosed
EP-0249096-A2 Renin-inhibiting amino acid derivatives MERCK PATENT GmbH (DE) 1987-12-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240262795-A1 PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 FLT3, MCL1, CSF3R SIRT6 686/4885DGAT1 4787/4885SOAT1 4680/4885
US-20250136558-A1 PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 FLT3, MCL1, JAK2 SIRT6 820/4885DGAT1 4804/4885SOAT1 4605/4885
US-11945785-B2 Pyrazine compounds as inhibitors of FLT3 FLT3, MCL1, JAK2 SIRT6 847/4885DGAT1 4776/4885SOAT1 4551/4885
US-20250312335-A1 FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR FLT3, MEN1, FEM1B SIRT6 785/4885DGAT1 4551/4885SOAT1 2937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.